The ROR1 data are sketchy, and lung toxicity clouds prospects.

A second Lilly Nectin-4 ADC features among the latest phase 1 initiations.

The group plays down upcoming interim analysis, but still hopes for accelerated approval.

One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.

The CDK4/6 inhibitor flunks its phase 3 study – a result that should have been foreseen five years ago.

Meanwhile, Bristol’s other competition in this disease looks set to come from China.

But investors don't fancy the company's chances, now seeing Aspen-06 as a fluke.